• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Position statement from the Indian Society of Gastroenterology, Cardiological Society of India, Indian Academy of Neurology and Vascular Society of India on gastrointestinal bleeding and endoscopic procedures in patients on antiplatelet and/or anticoagulant therapy
AbstractAntiplatelet and/or anticoagulant agents (collectively known as antithrombotic agents) are used to reduce the risk of thromboembolic events in patients with conditions such as atrial fibrillation, acute coronary syndrome, recurrent stroke prevention, deep vein thrombosis, hypercoagulable states and endoprostheses. Antithrombotic-associated gastrointestinal (GI) bleeding is an increasing burden due to the growing population of advanced age with multiple comorbidities and the expanding indications for the use of antiplatelet agents and anticoagulants. GI bleeding in antithrombotic users is associated with an increase...
Source: Indian Journal of Gastroenterology - June 5, 2023 Category: Gastroenterology Source Type: research

Periprocedural Management of Antithrombotics — Do Not Hold if you Can!
The decision to hold or not to hold antithrombotic (AT) medications for an endoscopic procedure rests on the balance of the procedural bleeding risk and the patient ’s risk of suffering a thromboembolic event (TE), including stroke, pulmonary embolism, deep vein thrombosis, angina, or a myocardial infarction. Guidelines have categorized procedures into those with high and low bleeding risk. AT may be continued if the bleeding risk is low. If the bleeding risk is high, AT medications should be held or modified.
Source: Clinical Gastroenterology and Hepatology - January 28, 2023 Category: Gastroenterology Authors: Heiko Pohl Tags: Editorial Source Type: research

Impaired coagulation, liver dysfunction and COVID-19: Discovering an intriguing relationship
World J Gastroenterol. 2022 Mar 21;28(11):1102-1112. doi: 10.3748/wjg.v28.i11.1102.ABSTRACTCoronavirus disease 2019 (COVID-19) is, at present, one of the most relevant global health problems. In the literature hepatic alterations have been described in COVID-19 patients, and they are mainly represented by worsening of underlying chronic liver disease leading to hepatic decompensation and liver failure with higher mortality. Several potential mechanisms used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to cause liver damage have been hypothesized. COVID-19 primary liver injury is less common than secondar...
Source: World Journal of Gastroenterology - April 18, 2022 Category: Gastroenterology Authors: Damiano D'Ardes Andrea Boccatonda Giulio Cocco Stefano Fabiani Ilaria Rossi Marco Bucci Maria Teresa Guagnano Cosima Schiavone Francesco Cipollone Source Type: research

Pages: 1  2  3  4  5